Finance

Lists
Outlook: 79.0% bullish·0.0% bearish
Go to analysis
CLDX:NASDAQ
Celldex Therapeutics Inc
$31.10
-1.21%
(-0.38) 1D
$31.55
+1.45% (+0.45)
After hours
Closed: Sep 25, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLDX...
Open
$31.48
High
$31.70
Low
$30.65
Mkt. cap
2.44B
Avg. vol.
1.36M
Volume
2.02M
52-wk high
$45.14
52-wk low
$22.10
EPS
-$4.36
Beta
0.84
Shares outstanding
78.53M
No. of employees
198
Open
$31.48
High
$31.70
Low
$30.65
Mkt. cap
2.44B
Avg. vol.
1.36M
Volume
2.02M
52-wk high
$45.14
52-wk low
$22.10
EPS
-$4.36
Beta
0.84
Shares outstanding
78.53M
No. of employees
198
News stories
From web sources and news partners
About Celldex Therapeutics Inc
CEO-
Employees198
Founded1983
HeadquartersHampton, New Jersey, United States
SectorBiotechnology
Websitecelldex.com
Analyst ratings
Based on 12 analysts giving stock ratings to CLDX in the past 3 months
Strong buy
Buy
11
Hold
1
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for CLDX in the last 3 months.
Highest
Current $31.10
$100.00 (+221.54%)
Average
$64.58 (+107.65%)
Lowest
$28.00 (-9.97%)
Analyst
Recommendation
Action
Price target
Projected
Date
Thomas Smith
Leerink Partners
Buy
Reiterated
$88.00
+183%
09/23/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
$28.00
-10%
09/22/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$100.00
+221.5%
09/22/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
$60.00
+92.9%
09/23/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Reiterated
$68.00
+118.6%
09/22/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$72.00
+131.5%
09/23/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$57.00
+83.3%
09/23/2026
Etzer Darout
Barclays
Buy
Maintained
$53.00
+70.4%
09/22/2026
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
$64.00
+105.8%
09/23/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$56.00
+80.1%
09/20/2026
Unknown Analyst
Jefferies
Buy
Maintained
$68.00
+118.6%
08/07/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Reiterated
$61.00
+96.1%
08/06/2026
David Dai
UBS
Buy
Maintained
$45.00
+44.7%
06/16/2026
Andy Chen
Wolfe Research
Buy
Maintained
$44.00
+41.5%
06/14/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
121.00K
15.00K
22.00K
Cost of goods sold
62.93M
75.33M
73.00M
67.54M
Cost of revenue
62.93M
75.33M
73.00M
67.54M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.69M
11.94M
11.45M
13.10M
Operating expense
10.69M
11.94M
11.45M
13.10M
Total operating expenses
73.62M
87.27M
84.45M
80.64M
Operating income
-73.62M
-87.15M
-84.44M
-80.62M
Other non operating income
-
-
-
-
EBT including unusual items
-67.04M
-81.32M
-78.68M
-73.50M
EBT excluding unusual items
-67.04M
-81.32M
-78.68M
-73.50M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-67.04M
-81.32M
-78.68M
-73.50M
Net profit margin
-
-67,204.13%
-524,566.67%
-334,104.55%
Earnings per share
-1.01
-1.22
-1.18
-0.94
Interest and investment income
6.57M
5.84M
5.75M
7.12M
Interest expense
-
-
-
-
Net interest expenses
6.57M
5.84M
5.75M
7.12M
Depreciation and amortization charges
-
-
-
-
EBITDA
-72.79M
-86.34M
-83.58M
-79.72M
Gain or loss from assets sale
6.00K
-
3.00K
1.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps